Paul Clancy, M.B.A. has served as chair of our board of directors since June 2022. Mr. Clancy is currently a visiting senior lecturer of Finance at Cornell University s Graduate School of Management, where he has been employed since August 2020, and has been an executive fellow at Harvard Business School since July 2020. Previously, Mr. Clancy served as executive vice president and senior advisor at Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) from November 2019 to July 2020 and executive vice president and chief financial officer from July 2017 to October 2019. Mr. Clancy also served as executive vice president and chief financial officer of Biogen, Inc. (NASDAQ: BIIB) from August 2007 to June 2017. Mr. Clancy also serves on the board of directors of Incyte Corporation (NASDAQ: INCY), since 2015. Mr. Clancy previously served on the boards of directors of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from September 2013 to June 2023, Xilio Therapeutics, Inc. (NASDAQ: XLO), from July 2020 to December 2025 and Exact Sciences Corporation (NASDAQ: EXAS), from March 2021 to March 2026. Mr. Clancy earned a B.S. in finance from Babson College and an M.B.A. from Columbia University. We believe Mr. Clancy s significant financial background in the biopharmaceutical industry and experience as a public company board member provide him with the appropriate set of skills to serve as a member of our board of directors.